Suchergebnisse - "van de Donk, Niels W C J"

PubPharm (7)

1

Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma : An Update

enthalten in: Drugs | 2018

von Nijhof, I. | van de Donk, N. | Zweegman, S. | +1

2

Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update

enthalten in: Drugs | 2017

von Nijhof, I. | van de Donk, N. | Zweegman, S. | +1

3

Erratum to : Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

enthalten in: Drugs | 2016

von Moreau, P. | van de Donk, N. | Miguel, J. | +17

ErratumFor: Drugs. 2016 May;76(8):853-67. doi: 10.1007/s40265-016-0573-4.. - PMID 27113582

4

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

enthalten in: Drugs | 2016

von Moreau, P. | van de Donk, N. | San Miguel, J. | +17

ErratumIn: Drugs. 2016 Jun;76(9):989-90. - PMID 27206917

5

Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

enthalten in: Drugs | 2016

von Moreau, P. | van de Donk, N. | Miguel, J. | +17

6

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

enthalten in: Drugs | 2016

von Moreau, P. | van de Donk, N. | Miguel, J. | +17

7

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

enthalten in: Drugs | 2016

von Moreau, P. | van de Donk, N. | Miguel, J. | +17

1
[1]